New York City-based Attune Pharmaceuticals Inc, a biotechnology company focused on treating rare diseases, has closed $23 million in Series B financing. Venrock Healthcare Partners led the round.
Source: Press Release
New York City-based Attune Pharmaceuticals Inc, a biotechnology company focused on treating rare diseases, has closed $23 million in Series B financing. Venrock Healthcare Partners led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: